Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicago Inc MDCGF



GREY:MDCGF - Post by User

Comment by wizwizon Feb 17, 2011 11:17pm
182 Views
Post# 18155701

RE: RE: RE: RE: RE: RE: who's ahead?

RE: RE: RE: RE: RE: RE: who's ahead?WHO conference feb 17-18,nvax to present why not mdg

MDG is definitely going to be there.

Wiz

https://www.pharmalive.com/News/index.cfm?articleid=761573&categoryid=40


Medicago invited to present at the 7th WHO's meeting on evaluation of pandemic influenza prototype vaccines in clinical trials


QUEBEC CITY, Feb. 15/PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnologycompany focused on developing highly effective and competitive vaccinesbased on proprietary manufacturing technologies and Virus-Like Particles(VLPs), today announced that Ms. Nathalie Landry, Vice President of Product Development, is invited to present at the 7thWHO meeting on evaluation of pandemic influenza prototype vaccines inclinical trials. The conference is being held at the World HealthOrganization's headquarters in Geneva, Switzerland, from February 18-19, 2011.The presentation, entitled "Advances in the clinical development ofplant-made influenza VLP vaccines", will discuss the Company's positiveinterim results from its phase II pandemic H5N1 influenza vaccineclinical trial.

The purpose of the World HealthOrganization's meeting is to review pandemic vaccines currently inclinical trials and to make recommendations on research activities thatwill contribute to the development of effective pandemic vaccines. Inattendance at this global gathering are representatives from governmentregulatory agencies, the leading vaccine companies, pharmaceuticalcompanies and research professionals.

The Company recently reported positiveinterim results from a Phase II human clinical trial with its pandemicH5N1 Influenza vaccine candidate. The vaccine was found to be safe, welltolerated and also induced a solid immune response. Final results fromthis study are currently expected in the second quarter of 2011.


<< Previous
Bullboard Posts
Next >>